The Root Cause Behind NB Audit Findings in MDR Tech Files
The MDR requires a level of design-to-clinical traceability that most legacy quality systems weren't built to maintain. A device family's technical file pulls together design history from Veeva Vault QualityDocs, clinical evaluation evidence that may live in SharePoint or Confluence, and PMCF plans that evolved through multiple Jira iterations. When the regulatory team assembles these manually under deadline pressure, broken links between design inputs and clinical evidence go undetected — until the Notified Body's auditor asks for the traceability matrix and the connections aren't there.
How an AI Agent Maintains a Live MDR Tech File Index
An AI Labor Company agent is trained on your Veeva Vault QualityDocs document hierarchies and prior Notified Body audit reports — including the specific gap patterns your NB has flagged historically. It maintains a live MDR technical documentation index with automated traceability links from design history records through to clinical evaluation and PMCF evidence. When a link breaks — because a document is revised, superseded, or not yet populated — the agent surfaces it to the regulatory VP with enough lead time to resolve it before the audit. The agent also monitors Greenlight Guru for design control records and flags any document-status mismatches that would undermine the submission package.
The Business Case: Protecting CE Mark Revenue for the Device Family
For a commercial device OEM, a CE mark is revenue. A major finding at NB audit doesn't just trigger a corrective action — it can suspend market access in EU jurisdictions while the deficiency is remediated. Teams managing MDR transitions with a continuous traceability agent typically reduce documentation-related gap findings by 50-70%, and the 60-day pre-audit surface window gives the regulatory team actionable resolution time rather than discovery time. The agent is typically live within 14 weeks. The investment — framed against $2M-$10M per device family in regulatory program costs — is primarily a risk and revenue protection play, not a headcount reduction story.
Can the agent handle multiple device families with different MDR classification levels?
Yes. The traceability logic is configured per device family and per MDR classification, so Class IIa and IIb devices with different clinical evaluation requirements can each maintain their own structured index within the same agent deployment.
Does this replace the regulatory writer who authors the CER?
No. The agent tracks traceability and surfaces gaps — it doesn't draft clinical evaluation content. The regulatory writer and RA team retain authorship and review responsibility for all clinical documentation. The agent is a completeness and consistency layer, not a content generator.